WO2017076103A1 - 自动化血糖仪 - Google Patents

自动化血糖仪 Download PDF

Info

Publication number
WO2017076103A1
WO2017076103A1 PCT/CN2016/096037 CN2016096037W WO2017076103A1 WO 2017076103 A1 WO2017076103 A1 WO 2017076103A1 CN 2016096037 W CN2016096037 W CN 2016096037W WO 2017076103 A1 WO2017076103 A1 WO 2017076103A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
blood glucose
pulse
signal
bluetooth
Prior art date
Application number
PCT/CN2016/096037
Other languages
English (en)
French (fr)
Inventor
李淑兰
Original Assignee
李淑兰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 李淑兰 filed Critical 李淑兰
Priority to CN201680035610.2A priority Critical patent/CN107683108A/zh
Publication of WO2017076103A1 publication Critical patent/WO2017076103A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
    • A61B5/14552—Details of sensors specially adapted therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813—Specially adapted to be attached to a specific body part
    • A61B5/6814—Head
    • A61B5/6815—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813—Specially adapted to be attached to a specific body part
    • A61B5/6825—Hand
    • A61B5/6826—Finger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7225—Details of analog processing, e.g. isolation amplifier, gain or sensitivity adjustment, filtering, baseline or drift compensation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program

Definitions

  • the present invention relates to the field of medical devices, and more particularly to an automated blood glucose meter.
  • Blood sugar refers to the glucose contained in the blood. Digested glucose enters the bloodstream from the small intestine and is transported to individual cells in the body, which is the main source of energy for the cells. Normal people's blood glucose levels are relatively stable and fall within a determinable range of blood glucose concentrations.
  • Blood sugar must be maintained at a certain level to maintain the needs of various organs and tissues in the body. Blood glucose levels generally increase after eating for one to two hours, while minimizing breakfast. Unbalanced blood glucose levels can lead to a variety of diseases. Hyperglycemia and excessive hypoglycemia with persistently high blood glucose levels can have serious effects on the body, and persistent hyperglycemia caused by a variety of causes can cause diabetes. It is also the most significant disease associated with blood glucose levels.
  • the present invention proposes an automatic blood glucose meter, which can improve the structure of the backward blood glucose meter, integrate pulse detection into the blood glucose meter, broaden the range of physiological parameters detected, improve the accuracy of blood glucose detection, and establish automatic blood sugar control.
  • the insulin supply system reduces manual participation.
  • it can improve the existing Bluetooth communication mechanism, improve the speed and efficiency of wireless data transmission, and thus improve the intelligence level of the blood glucose meter as a whole.
  • the present invention provides an automatic blood glucose meter, which simultaneously concentrates the pulse detecting device and the blood glucose detecting device in one detecting instrument, optimizes the structure of the existing blood glucose detecting device, and improves blood sugar detecting. Accuracy, at the same time, the addition of insulin pump and insulin supply control mechanism to achieve automatic control of blood glucose concentration, it is particularly important to improve the communication efficiency of the wireless connection of blood glucose instruments by improving the matching mechanism and connection mechanism of the existing Bluetooth communication interface.
  • an automated blood glucose meter comprising an insulin driving device, an insulin pump, a pulse detecting device, a blood glucose detecting device, and a Freescale IMX6 processor, the pulse detecting device and the The blood glucose detecting device is respectively configured to extract pulse data and blood glucose data of the test subject, and the Freescale IMX6 processor is respectively connected to the insulin driving device, the pulse detecting device and the blood glucose detecting device, based on the The pulse data of the pulse detecting device determines whether a pulse abnormality identification signal is issued, and determines whether to control the insulin driving device to drive the insulin pump to inject insulin for the test subject based on the blood glucose data of the blood glucose detecting device.
  • the automated blood glucose meter includes: a first resistor, one end is connected to the 5V power source, the other end is connected to the positive end of the infrared receiving diode; and the second resistor is connected to the 5V power source at one end, and the other end is connected to the third One end of the resistor is connected; the third resistor is grounded at the other end and has the same resistance as the second resistor; the first dual op amp is used to generate a reference voltage of 2.5V, the positive end and the other end of the second resistor Connected, the negative end is connected to one end of the first capacitor, the output end is connected to the negative end of the infrared emitting diode, the negative end is also connected to the negative end of the infrared emitting diode; the first capacitor is grounded at the other end; the fourth resistor, one end and the infrared The negative terminal of the transmitting diode is connected; the second dual operational amplifier has a positive terminal connected to the other end of the fourth resistor, a negative
  • a low identification signal for pre-storing a predetermined volume of insulin; a liquid level detecting device located at the insulin In the device, for detecting the insulin liquid level in the insulin storage device in real time, and issuing an insulin deficiency alarm signal when the insulin liquid level is equal to or lower than the preset reference liquid level, the liquid level detecting device is also associated with the Phase One a Carl IMX6 processor is coupled to transmit the insulin deficiency warning signal to the Freescale IMX6 processor; an insulin driven device coupled to the Freescale IMX6 processor when the blood glucose concentration is too high to receive an identification signal And determining an insulin pump driving signal according to a difference between the blood glucose concentration forwarded by the Freescale IMX6 processor and the preset blood glucose upper limit concentration, wherein the insulin pump driving signal determines the amount and speed of the insulin supply of the insulin pump An insulin pump connected to the insulin storage device and the insulin injection device, respectively, connected to the insulin driving device for injecting insulin in the insulin storage device through insulin under the control of the insulin driving device.
  • the serial communication circuit is an RS232 serial communication interface.
  • the Freescale IMX6 processor simultaneously issues an abnormal state signal when a pulse abnormality recognition signal, a hyperglycemia recognition signal, or a hypoglycemia recognition signal is issued, otherwise,
  • the Freescale IMX6 processor simultaneously signals a normal status.
  • the medical therapy apparatus further includes: a wireless communication circuit coupled to the Freescale IMX6 processor for transmitting an abnormal state signal or a normal state signal.
  • the wireless communication circuit is a 3G mobile communication interface or a 4G mobile communication interface.
  • the medical treatment apparatus further includes: a FLASH memory chip connected to the Freescale IMX6 processor for pre-storing a preset pulse range, a preset blood glucose upper limit concentration, and Preset the lower blood glucose concentration.
  • Figure 1 is a block diagram showing the configuration of a first embodiment of an automated blood glucose meter of the present invention.
  • the sugar in the blood is called blood sugar, and in most cases it is glucose. Most of the energy required for cell activity in various tissues in the body comes from glucose, so blood sugar must be kept at a certain level to maintain the needs of various organs and tissues in the body.
  • the concentration of blood sugar in the human body is usually controlled to a very narrow range, and blood sugar too high or too low will have a certain impact on people.
  • blood sugar too high or too low will have a certain impact on people.
  • a variety of blood glucose meters have appeared on the market, especially for patients with high blood pressure.
  • the prior art blood glucose meter has a single detection parameter, a backward detection mechanism, and lacks an automatic control mechanism for blood glucose detection and insulin supply.
  • the wireless communication interface is matched and the connection efficiency is low, and the hospital and the patient cannot be satisfied. request.
  • the present invention constructs an automated blood glucose meter that integrates a structurally optimized high-precision pulse monitoring device and a blood glucose monitoring device into a single instrument, while using an automatic control mode for blood glucose detection and insulin supply, and optimized
  • the Bluetooth communication interface provides more convenience for the use of patients and hospitals.
  • FIG. 1 is a block diagram showing the structure of a first embodiment of an automated blood glucose meter according to the present invention, which includes an insulin driving device, an insulin pump, a pulse detecting device, a blood glucose detecting device, and a Freescale IMX6 processor, the pulse detecting The device and the blood glucose detecting device are respectively configured to extract pulse data and blood glucose data of the test subject, and the Freescale IMX6 processor is respectively connected to the insulin driving device, the pulse detecting device and the blood glucose detecting device, Determining whether to issue a pulse abnormality identification signal based on pulse data of the pulse detecting device, determining whether to control the insulin driving device to drive the insulin pump to inject insulin for a test subject based on blood glucose data of the blood glucose detecting device.
  • the medical treatment apparatus comprises: a first resistor, one end is connected to the 5V power source, and the other end is connected to the positive end of the infrared receiving diode; the second resistor is connected at one end to the 5V power source, and the other end is connected to one end of the third resistor; The resistor is grounded at the other end and has the same resistance as the second resistor.
  • the medical treatment apparatus comprises: a first dual operational amplifier for generating a reference voltage of 2.5V, a positive end of which is connected to the other end of the second resistor, a negative terminal connected to one end of the first capacitor, and an output end and infrared emission
  • the negative terminal of the diode is connected, the negative terminal is also connected to the negative terminal of the infrared emitting diode; the first capacitor is grounded at the other end; the fourth resistor is connected at one end to the negative terminal of the infrared emitting diode; the second dual operational amplifier, the positive terminal is The other end of the fourth resistor is connected, the negative terminal is connected to the positive terminal of the infrared receiving diode, and the output terminal is used as the pulse voltage.
  • the medical treatment apparatus includes: a fifth resistor connected in parallel between the second dual operational amplifier negative terminal and the second dual operational amplifier output terminal; and a second capacitor connected in parallel to the second dual operational amplifier negative terminal and the second Between the output terminals of the dual op amps; the infrared emitting diode is disposed at the capillary position of the ear of the tested person to emit infrared light, and the negative end of the infrared emitting diode is connected with the positive end of the infrared receiving diode; the infrared receiving diode is set The capillary position of the ear of the test subject is located at a relative position of the infrared emitting diode for receiving infrared light transmitted through the capillaries of the ear of the test subject.
  • the medical therapy apparatus includes: a direct digital frequency synthesizer for generating a sine wave signal whose frequency and phase can be adjusted for use as a frequency mixing source for mixing; a pulse sequence generator for generating a pulse sequence; a mixer Connected to the direct digital frequency synthesizer and the pulse sequence generator respectively, and the sinusoidal signal is mixed and modulated by a pulse sequence; a power amplifier is connected to the mixer for mixing and mixing The signal is amplified.
  • the medical treatment apparatus comprises: a switching power supply, which is used as an interface circuit between the probe and the power amplifier, and loads the amplified signal into the RF transceiver coil of the probe; the NdFeB permanent magnet type magnet structure accommodates the tested person A static magnetic field with uniform field strength is generated in the space of the finger; the probe is placed at the finger position of the tested person, and the RF transceiver coil is wound to send the loaded signal into the NdFeB permanent magnet type magnet structure to generate nuclear magnetic resonance phenomenon. It is also used to send out the attenuation signal obtained after the hydrogen proton resonance in the finger of the person being tested.
  • the medical treatment apparatus includes: a Freescale IMX6 processor coupled to the probe to receive the attenuation signal No., analyzing the spectral line of the attenuation signal, and calculating the proportion of glucose therein, thereby obtaining the blood glucose concentration of the measured person, the Freescale IMX6 processor is also connected to the output of the second dual operational amplifier Obtaining the pulse voltage, and when the pulse voltage is outside the preset pulse range, issuing a pulse abnormality identification signal, and when the blood glucose concentration is at a preset upper blood glucose upper limit concentration, emitting a blood glucose concentration excessively high identification signal, when The blood glucose concentration emits a low blood glucose concentration low recognition signal when the blood glucose lower limit concentration is preset.
  • the medical treatment apparatus includes: an insulin storage device for pre-storing a preset volume of insulin; a liquid level detecting device located in the insulin storage device for detecting an insulin liquid level in the insulin storage device in real time, and in insulin When the liquid level is equal to or lower than the preset reference liquid level, an insulin deficiency alarm signal is issued, and the liquid level detecting device is further connected with the Freescale IMX6 processor to send the insulin deficiency alarm signal to the Phase One Carl IMX6 processor.
  • the medical treatment apparatus includes: an insulin driving device connected to the Freescale IMX6 processor, and when receiving the blood glucose concentration excessively high identification signal, according to the blood glucose concentration and the volume forwarded by the Freescale IMX6 processor The difference between the preset blood glucose upper limit concentration determines an insulin pump drive signal, the insulin pump drive signal determines the magnitude and speed of the insulin pump supply insulin; the insulin pump is connected to the insulin storage device and the insulin injection device respectively And connecting to the insulin driving device, for injecting insulin in the insulin storage device into the body of the test subject through the insulin injection device under the control of the insulin driving device.
  • the medical treatment apparatus comprises: an insulin injection device, which is detachably embedded in the body of the test object for injecting insulin into the test subject; the serial communication circuit is located between the Freescale IMX6 processor and the Bluetooth matching communication device, The blood glucose concentration and the insulin deficiency alarm signal are sent to the Bluetooth matching communication device.
  • the medical treatment apparatus includes: a Bluetooth matching communication device, configured to wirelessly transmit the blood glucose concentration and the insulin deficiency alarm signal to a connected target Bluetooth device; the Bluetooth matching communication device includes a first search sub-device, Two search sub-devices and matching connection sub-devices.
  • the first search sub-device determines the Bluetooth piconet with the highest Bluetooth MAC address concentration as the target piconet according to the MAC address concentration in the Bluetooth scatter network, and one Bluetooth scatter network is composed of multiple Bluetooth piconets; the second search sub-device, The first search sub-device is connected, in the target piconet, searching for one or more Bluetooth-matched communication devices with a quantity of not more than 7 ranked first by signal strength as one or more target Bluetooth devices; And the child device is connected to the second search sub-device to initiate a Bluetooth communication connection with the one or more target Bluetooth devices.
  • the pulse voltage when there is no pulse between the infrared emitting diode and the infrared receiving diode, the pulse voltage is 2.5V, and when there is a beating pulse between the infrared emitting diode and the infrared receiving diode, the blood pulse makes the ear transmissivity worse, the pulse voltage More than 2.5V; among them, the first dual op amp and the second dual op amp are TI's dual op amps.
  • the RF transceiver coil wound by the probe is one of a birdcage coil, a spiral coil, a saddle coil, a phased array coil and a loop coil; wherein the frequency synthesis used by the direct digital frequency synthesizer is directly selected One of digital synthesis, analog phase-locked loops, and digital phase-locked loops.
  • the number of the one or more target Bluetooth devices is 7, when there is a signal Bluetooth in the target piconet
  • the number of matching communication devices is less than 7
  • the number of the one or more target Bluetooth devices is the number of Bluetooth-matched communication devices having signals in the target piconet.
  • the serial communication circuit is an RS232 serial communication interface
  • the Freescale IMX6 processor simultaneously issues an abnormal status signal when a pulse abnormality signal, a hyperglycemia signal, or a hypoglycemia signal is issued.
  • the medical treatment apparatus further includes: a wireless communication circuit connected to the Freescale IMX6 processor for transmitting an abnormal state signal or a normal state signal; the wireless communication circuit being a 3G mobile communication interface or a 4G mobile communication interface;
  • the medical treatment apparatus further includes: a FLASH memory chip connected to the Freescale IMX6 processor for pre-storing a preset pulse range, a preset blood glucose upper limit concentration, and a preset lower blood glucose lower limit concentration.
  • an operational amplifier (referred to as an "op amp”) is a circuit unit with a very high amplification factor. In the actual circuit, usually combined with the feedback network to form a certain functional module. He is an amplifier with a special coupling circuit and feedback.
  • the output signal can be the result of mathematical operations such as input signal addition, subtraction or differentiation, integration, and the like. Because it was first used in analog computers to implement mathematical operations, it was named “Operational Amplifier".
  • An op amp is a functional unit named from a functional point of view and can be implemented in discrete devices or in semiconductor chips. With the development of semiconductor technology, most of the op amps exist in the form of a single chip. There are many types of op amps, which are widely used in the electronics industry.
  • the prior art blood glucose instrument has a backward structure and a poor wireless communication function, optimizes the structure of the existing blood glucose instrument, and adds a pulse detecting device and an automatic blood glucose concentration control device, and also improves the present There is communication performance of the Bluetooth communication interface, thereby increasing the level of its medical services.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Signal Processing (AREA)
  • Cardiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Power Engineering (AREA)
  • Otolaryngology (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Psychiatry (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

一种自动化血糖仪，包括胰岛素驱动设备（1）、胰岛素泵（2）、脉搏检测设备（3）、血糖检测设备（4）和飞思卡尔IMX6处理器（5）。脉搏检测设备（3）和血糖检测设备（4）分别用于提取被测人员的脉搏数据和血糖数据。飞思卡尔IMX6处理器（5）与胰岛素驱动设备（1）、脉搏检测设备（3）和血糖检测设备（4）分别连接，基于脉搏检测设备（3）的脉搏数据确定是否发出脉搏异常识别信号，基于血糖检测设备（4）的血糖数据确定是否控制胰岛素驱动设备（1）以驱动胰岛素泵（2）为被测人员注射胰岛素。通过该自动化血糖仪，能对脉搏信息是否异常进行自动检测，并且还能实现胰岛素注射的自动化控制。

Description

自动化血糖仪 技术领域
本发明涉及医疗器件领域，尤其涉及一种自动化血糖仪。
背景技术
血糖，指的是血液中所含的葡萄糖。消化后的葡萄糖由小肠进入血液，并被运输到机体中的各个细胞，是细胞的主要能量来源。正常人的血糖浓度相对稳定，落在一个可确定的血糖浓度范围之内。
血糖必须保持一定的水平才能维持体内各个器官和组织的需要。血糖浓度一般在进食一到二个小时后升高，而在早餐降到最低。血糖浓度失调会导致多种疾病，持续性血糖浓度过高的高血糖和过低的低血糖都会给人们身体造成严重的影响，而由多种原因导致的持续性高血糖就会引起糖尿病，这也是血糖浓度相关的最显著的疾病。
现有技术中存在一些检测血糖的医疗仪器，但这些血糖仪都存在以下缺陷：(1)检测模式单一，只能检测血糖浓度；(2)检测机制落后，结构冗余度过高，精度满足不了日趋增加的精度需求；(3)没有血糖检测和胰岛素供给的控制机制，无法根据被测人体的血糖含量自适应调整被测人员的胰岛素的供给参数，例如，供给速度、供给量等，还需要人工观察血糖含量、人工决策胰岛素供给参数，自动化水平落后；(4)无线通信接口匮乏，不能将与血糖相关的各个参数及时反馈到医疗服务器端，即使存在一些简单的无线通信接口，例如蓝牙通信接口，其匹配机制和连接机制效率低下，满足不了医疗器件的高速度传输数据的要求。
为此，本发明提出了一种自动化血糖仪，能够改善落后的血糖仪的结构，将脉搏检测融入到血糖仪中，拓宽检测的生理参数的范围，提高血糖检测的精度，能够建立血糖自动控制的胰岛素供给体系，减少人工参与，另外，还能够改善现有的蓝牙通信机制，提高无线数据传输的速度和效率，从而，从整体上提高血糖仪的智能化水平。
发明内容
为了解决现有技术存在的技术问题，本发明提供了一种自动化血糖仪，将脉搏检测设备和血糖检测设备集中在一个检测仪器内同时工作，优化现有的血糖检测设备的结构，提高血糖检测的精度，同时，加入胰岛素泵和胰岛素供给控制机制，实现血糖浓度的自动控制，尤为重要的是，通过改善现有蓝牙通信接口的匹配机制和连接机制，提高血糖仪器无线连接的通信效率。
根据本发明的一方面，提供了一种自动化血糖仪，所述医学治疗仪包括胰岛素驱动设备、胰岛素泵、脉搏检测设备、血糖检测设备和飞思卡尔IMX6处理器，所述脉搏检测设备和所述血糖检测设备分别用于提取被测人员的脉搏数据和血糖数据，所述飞思卡尔IMX6处理器与所述胰岛素驱动设备、所述脉搏检测设备和所述血糖检测设备分别连接，基于所述脉搏检测设备的脉搏数据确定是否发出脉搏异常识别信号，基于所述血糖检测设备的血糖数据确定是否控制所述胰岛素驱动设备以驱动所述胰岛素泵为被测人员注射胰岛素。
更具体地，在所述自动化血糖仪中，包括：第一电阻，一端与5V电源连接，另一端与红外接收二极管的正端连接；第二电阻，一端与5V电源连接，另一端与第三电阻的一端连接；第三电阻，另一端接地，并具有与第二电阻相同的阻值；第一双路运算放大器，用于产生2.5V的基准电压，其正端与第二电阻的另一端连接，负端与第一电容的一端连接，输出端与红外发射二极管的负端连接，负端还与红外发射二极管的负端连接；第一电容，另一端接地；第四电阻，一端与红外发射二极管的负端连接；第二双路运算放大器，正端与第四电阻的另一端连接，负端与红外接收二极管的正端连接，输出端作为脉搏电压；第五电阻，并联在第二双路运算放大器负端和第二双路运算放大器输出端之间；第二电容，并联在第二双路运算放大器负端和第二双路运算放大器输出端之间；红外发射二极管，设置在被测人员耳部毛细血管位置，用于发射红外光，红外发射二极管的负端与红外接收二极管的正端连接；红外接收二极管，设置在被测人员耳部毛细血管位置，位于所述红外发射二极管的相对位置，用于接收透射被测人员耳部毛细血管后的红外光；直接数字频率合成器，用于产生频率和相位能够调整的正弦波信号以作为射频频率源用作混频使用；脉冲序列发生器，用于产生脉冲序列；混频器，与所述直接数字频率合成器和所述脉冲序列发生器分别连接，采用脉冲序列对正弦波信号进行混频调制；功率放大器，与所述混频器连接，用于将混频调制后的信号进行放大；开关电源，用作探头与功率放大器之间的接口电路，将放大后的信号加载到探头的射频收发线圈中；钕铁硼永磁型磁体结构，在容纳被测人员手指的空间内产生一个场强均匀的静态磁场；探头，放置在被测人员手指位置，缠绕射频收发线圈以将加载的信号送入所述钕铁硼永磁型磁体结构内，产生核磁共振现象，还用于将经过被测人员手指内氢质子共振后获得的衰减信号送出；飞思卡尔IMX6处理器，与所述探头连接，接收所述衰减信号，分析所述衰减信号的谱线，并计算其中葡萄糖所占比例，从而获取被测人员的血糖浓度，所述飞思卡尔IMX6处理器还与所述第二双路运算放大器的输出端连接以获得所述脉搏电压，并当所述脉搏电压在预设脉搏范围之外时，发出脉搏异常识别信号，当所述血糖浓度在预设血糖上限浓度时，发出血糖浓度过高识别信号，当所述血糖浓度在预设血糖下限浓度时，发出血糖浓度过低识别信号；胰岛素存储设备，用于预先存储预设容量的胰岛素；液位检测设备，位于所述胰岛素存储设备内，用于实时检测胰岛素存储设备内的胰岛素液位，并在胰岛素液位等于或低于预设基准液位时，发出胰岛素不足报警信号，所述液位检测设备还与所述飞思卡尔IMX6处理器连接以将所述胰岛素不足报警信号发送给所述飞思卡尔IMX6处理器；胰岛素驱动设备，与所述飞思卡尔IMX6处理器连接，当接收到所述血糖浓度过高识别信号时，根据所述飞思卡尔IMX6处理器转发的血糖浓度和所述预设血糖上限浓度的差值确定胰岛素泵驱动信号，所述胰岛素泵驱动信号决定了胰岛素泵的供应胰岛素的量值和速度；胰岛素泵，与所述胰岛素存储设备和胰岛素注射设备分别相接，与所述胰岛素驱动设备连接，用于在所述胰岛素驱动设备的控制下，将所述胰岛素存储设备内的胰岛素通过胰岛素注射设备注射到被测人员体内；胰岛素注射设备，可拆卸式埋设在被测人员体内，用于向被测人员注射胰岛素；串口通信电路，位于飞思卡尔IMX6处理器与蓝牙匹配通信设备之间，用于将所述血糖浓度和所述胰岛素不足报警信号发送到蓝牙匹配通信设备；蓝牙匹配通信设备，用于将所述血糖浓度和所述胰岛素不足报警信号无线发送到连接上的目标蓝牙设备；所述蓝牙匹配通信设备包括第一搜索子设备、第二搜索子设备和匹配连接子设备；其中，第一搜索子设备，根据蓝牙散射网中MAC地址浓度确定蓝牙MAC地 址浓度最高的蓝牙微微网作为目标微微网，一个蓝牙散射网由多个蓝牙微微网组成；第二搜索子设备，与所述第一搜索子设备连接，在所述目标微微网中，寻找按信号强度排名在前的、数量不大于7的一个或多个蓝牙匹配通信设备作为一个或多个目标蓝牙设备；设备连接子设备，与所述第二搜索子设备连接，启动与所述一个或多个目标蓝牙设备的蓝牙通信连接；其中，当红外发射二极管和红外接收二极管之间无脉搏时，脉搏电压为2.5V，当红外发射二极管和红外接收二极管之间存在跳动的脉搏时，血脉使耳部透光性变差，脉搏电压大于2.5V；其中，第一双路运算放大器和第二双路运算放大器都为TI公司的双路运算放大器；其中，所述探头缠绕的射频收发线圈为鸟笼线圈、螺旋管线圈、鞍状线圈、相控阵列线圈和环状线圈中的一种；其中，直接数字频率合成器所采用的频率合成选用直接数字合成、模拟锁相环和数字锁相环中的一种；其中，当所述目标微微网中有信号的蓝牙匹配通信设备的数量为大于等于7时，所述一个或多个目标蓝牙设备的数量为7个，当所述目标微微网中有信号的蓝牙匹配通信设备的数量为小于7时，所述一个或多个目标蓝牙设备的数量为所述目标微微网中有信号的蓝牙匹配通信设备的数量。
更具体地，在所述自动化血糖仪中：所述串口通信电路为RS232串行通信接口。
更具体地，在所述自动化血糖仪中：所述飞思卡尔IMX6处理器在发出脉搏异常识别信号、血糖过高识别信号或血糖过低识别信号时，同时发出异常状态信号，否则，所述飞思卡尔IMX6处理器同时发出正常状态信号。
更具体地，在所述自动化血糖仪中，所述医学治疗仪还包括：无线通信电路，与所述飞思卡尔IMX6处理器连接，用于发送异常状态信号或正常状态信号。
更具体地，在所述自动化血糖仪中：所述无线通信电路为3G移动通信接口或4G移动通信接口。
更具体地，在所述自动化血糖仪中，所述医学治疗仪还包括：FLASH存储芯片，与所述飞思卡尔IMX6处理器连接，用于预先存储预设脉搏范围、预设血糖上限浓度和预设血糖下限浓度。
附图说明
以下将结合附图对本发明的实施方案进行描述，其中：
图1为本发明的自动化血糖仪的第一实施例的结构方框图。
附图标记：1胰岛素驱动设备；2胰岛素泵；3脉搏检测设备；4血糖检测设备；5飞思卡尔IMX6处理器
具体实施方式
下面将参照附图对本发明的自动化血糖仪的实施方案进行详细说明。
血液中的糖称为血糖，绝大多数情况下都是葡萄糖。体内各组织细胞活动所需的能量大部分来自葡萄糖，所以血糖必须保持在一定水平才能维持体内各器官和组织的需求。
人体中的血糖的浓度通常被控制在一个很窄的范围内，血糖过高或过低都会给人们造成一定的影响。为了有效检测人体内的血糖浓度，市面上出现了多种血糖仪，尤其为患有高血压的病人所青睐。
然而，现有技术中的血糖仪检测参数单一、检测机制落后，缺乏血糖检测和胰岛素供给的自动控制机制，同时，配有的无线通信接口匹配和连接效率低下，已经满足不了医院和病人的现有要求。
为此，本发明搭建了一种自动化血糖仪，将经过结构优化的高精度的脉搏监控设备和血糖监控设备集成在一个检测仪器中，同时采用血糖检测和胰岛素供给的自动控制模式以及优化后的蓝牙通信接口，为病人和医院的使用提供更多的方便。
图1为本发明的自动化血糖仪的第一实施例的结构方框图，所述医学治疗仪包括胰岛素驱动设备、胰岛素泵、脉搏检测设备、血糖检测设备和飞思卡尔IMX6处理器，所述脉搏检测设备和所述血糖检测设备分别用于提取被测人员的脉搏数据和血糖数据，所述飞思卡尔IMX6处理器与所述胰岛素驱动设备、所述脉搏检测设备和所述血糖检测设备分别连接，基于所述脉搏检测设备的脉搏数据确定是否发出脉搏异常识别信号，基于所述血糖检测设备的血糖数据确定是否控制所述胰岛素驱动设备以驱动所述胰岛素泵为被测人员注射胰岛素。
接着，继续对本发明的自动化血糖仪的第二实施例的具体结构进行进一步的说明。
所述医学治疗仪包括：第一电阻，一端与5V电源连接，另一端与红外接收二极管的正端连接；第二电阻，一端与5V电源连接，另一端与第三电阻的一端连接；第三电阻，另一端接地，并具有与第二电阻相同的阻值。
所述医学治疗仪包括：第一双路运算放大器，用于产生2.5V的基准电压，其正端与第二电阻的另一端连接，负端与第一电容的一端连接，输出端与红外发射二极管的负端连接，负端还与红外发射二极管的负端连接；第一电容，另一端接地；第四电阻，一端与红外发射二极管的负端连接；第二双路运算放大器，正端与第四电阻的另一端连接，负端与红外接收二极管的正端连接，输出端作为脉搏电压。
所述医学治疗仪包括：第五电阻，并联在第二双路运算放大器负端和第二双路运算放大器输出端之间；第二电容，并联在第二双路运算放大器负端和第二双路运算放大器输出端之间；红外发射二极管，设置在被测人员耳部毛细血管位置，用于发射红外光，红外发射二极管的负端与红外接收二极管的正端连接；红外接收二极管，设置在被测人员耳部毛细血管位置，位于所述红外发射二极管的相对位置，用于接收透射被测人员耳部毛细血管后的红外光。
所述医学治疗仪包括：直接数字频率合成器，用于产生频率和相位能够调整的正弦波信号以作为射频频率源用作混频使用；脉冲序列发生器，用于产生脉冲序列；混频器，与所述直接数字频率合成器和所述脉冲序列发生器分别连接，采用脉冲序列对正弦波信号进行混频调制；功率放大器，与所述混频器连接，用于将混频调制后的信号进行放大。
所述医学治疗仪包括：开关电源，用作探头与功率放大器之间的接口电路，将放大后的信号加载到探头的射频收发线圈中；钕铁硼永磁型磁体结构，在容纳被测人员手指的空间内产生一个场强均匀的静态磁场；探头，放置在被测人员手指位置，缠绕射频收发线圈以将加载的信号送入所述钕铁硼永磁型磁体结构内，产生核磁共振现象，还用于将经过被测人员手指内氢质子共振后获得的衰减信号送出。
所述医学治疗仪包括：飞思卡尔IMX6处理器，与所述探头连接，接收所述衰减信 号，分析所述衰减信号的谱线，并计算其中葡萄糖所占比例，从而获取被测人员的血糖浓度，所述飞思卡尔IMX6处理器还与所述第二双路运算放大器的输出端连接以获得所述脉搏电压，并当所述脉搏电压在预设脉搏范围之外时，发出脉搏异常识别信号，当所述血糖浓度在预设血糖上限浓度时，发出血糖浓度过高识别信号，当所述血糖浓度在预设血糖下限浓度时，发出血糖浓度过低识别信号。
所述医学治疗仪包括：胰岛素存储设备，用于预先存储预设容量的胰岛素；液位检测设备，位于所述胰岛素存储设备内，用于实时检测胰岛素存储设备内的胰岛素液位，并在胰岛素液位等于或低于预设基准液位时，发出胰岛素不足报警信号，所述液位检测设备还与所述飞思卡尔IMX6处理器连接以将所述胰岛素不足报警信号发送给所述飞思卡尔IMX6处理器。
所述医学治疗仪包括：胰岛素驱动设备，与所述飞思卡尔IMX6处理器连接，当接收到所述血糖浓度过高识别信号时，根据所述飞思卡尔IMX6处理器转发的血糖浓度和所述预设血糖上限浓度的差值确定胰岛素泵驱动信号，所述胰岛素泵驱动信号决定了胰岛素泵的供应胰岛素的量值和速度；胰岛素泵，与所述胰岛素存储设备和胰岛素注射设备分别相接，与所述胰岛素驱动设备连接，用于在所述胰岛素驱动设备的控制下，将所述胰岛素存储设备内的胰岛素通过胰岛素注射设备注射到被测人员体内。
所述医学治疗仪包括：胰岛素注射设备，可拆卸式埋设在被测人员体内，用于向被测人员注射胰岛素；串口通信电路，位于飞思卡尔IMX6处理器与蓝牙匹配通信设备之间，用于将所述血糖浓度和所述胰岛素不足报警信号发送到蓝牙匹配通信设备。
所述医学治疗仪包括：蓝牙匹配通信设备，用于将所述血糖浓度和所述胰岛素不足报警信号无线发送到连接上的目标蓝牙设备；所述蓝牙匹配通信设备包括第一搜索子设备、第二搜索子设备和匹配连接子设备。
其中，第一搜索子设备，根据蓝牙散射网中MAC地址浓度确定蓝牙MAC地址浓度最高的蓝牙微微网作为目标微微网，一个蓝牙散射网由多个蓝牙微微网组成；第二搜索子设备，与所述第一搜索子设备连接，在所述目标微微网中，寻找按信号强度排名在前的、数量不大于7的一个或多个蓝牙匹配通信设备作为一个或多个目标蓝牙设备；设备连接子设备，与所述第二搜索子设备连接，启动与所述一个或多个目标蓝牙设备的蓝牙通信连接。
其中，当红外发射二极管和红外接收二极管之间无脉搏时，脉搏电压为2.5V，当红外发射二极管和红外接收二极管之间存在跳动的脉搏时，血脉使耳部透光性变差，脉搏电压大于2.5V；其中，第一双路运算放大器和第二双路运算放大器都为TI公司的双路运算放大器。
其中，所述探头缠绕的射频收发线圈为鸟笼线圈、螺旋管线圈、鞍状线圈、相控阵列线圈和环状线圈中的一种；其中，直接数字频率合成器所采用的频率合成选用直接数字合成、模拟锁相环和数字锁相环中的一种。
其中，当所述目标微微网中有信号的蓝牙匹配通信设备的数量为大于等于7时，所述一个或多个目标蓝牙设备的数量为7个，当所述目标微微网中有信号的蓝牙匹配通信设备的数量为小于7时，所述一个或多个目标蓝牙设备的数量为所述目标微微网中有信号的蓝牙匹配通信设备的数量。
可选地，在所述自动化血糖仪中：所述串口通信电路为RS232串行通信接口；所述 飞思卡尔IMX6处理器在发出脉搏异常识别信号、血糖过高识别信号或血糖过低识别信号时，同时发出异常状态信号，否则，所述飞思卡尔IMX6处理器同时发出正常状态信号；所述医学治疗仪还包括：无线通信电路，与所述飞思卡尔IMX6处理器连接，用于发送异常状态信号或正常状态信号；所述无线通信电路为3G移动通信接口或4G移动通信接口；所述医学治疗仪还包括：FLASH存储芯片，与所述飞思卡尔IMX6处理器连接，用于预先存储预设脉搏范围、预设血糖上限浓度和预设血糖下限浓度。
另外，运算放大器(简称“运放”)是具有很高放大倍数的电路单元。在实际电路中，通常结合反馈网络共同组成某种功能模块。他是一种带有特殊耦合电路及反馈的放大器。其输出信号可以是输入信号加、减或微分、积分等数学运算的结果。由于早期应用于模拟计算机中，用以实现数学运算，故得名“运算放大器”。
运放是一个从功能的角度命名的电路单元，可以由分立的器件实现，也可以实现在半导体芯片当中。随着半导体技术的发展，大部分的运放是以单芯片的形式存在。运放的种类繁多，广泛应用于电子行业当中。
采用本发明的自动化血糖仪，针对现有技术中血糖仪器结构落后且无线通信功能差的技术问题，优化现有的血糖仪器的结构，加入脉搏检测设备和血糖浓度自动控制设备，同时还提高现有蓝牙通信接口的通信性能，从而提高其医疗服务的水平。
可以理解的是，虽然本发明已以较佳实施例披露如上，然而上述实施例并非用以限定本发明。对于任何熟悉本领域的技术人员而言，在不脱离本发明技术方案范围情况下，都可利用上述揭示的技术内容对本发明技术方案做出许多可能的变动和修饰，或修改为等同变化的等效实施例。因此，凡是未脱离本发明技术方案的内容，依据本发明的技术实质对以上实施例所做的任何简单修改、等同变化及修饰，均仍属于本发明技术方案保护的范围内。

Claims (7)

  1. 一种自动化血糖仪，所述医学治疗仪包括胰岛素驱动设备、胰岛素泵、脉搏检测设备、血糖检测设备和飞思卡尔IMX6处理器，所述脉搏检测设备和所述血糖检测设备分别用于提取被测人员的脉搏数据和血糖数据，所述飞思卡尔IMX6处理器与所述胰岛素驱动设备、所述脉搏检测设备和所述血糖检测设备分别连接，基于所述脉搏检测设备的脉搏数据确定是否发出脉搏异常识别信号，基于所述血糖检测设备的血糖数据确定是否控制所述胰岛素驱动设备以驱动所述胰岛素泵为被测人员注射胰岛素。
  2. 如权利要求1所述的自动化血糖仪，其特征在于，所述医学治疗仪包括：
    第一电阻，一端与5V电源连接，另一端与红外接收二极管的正端连接；
    第二电阻，一端与5V电源连接，另一端与第三电阻的一端连接；
    第三电阻，另一端接地，并具有与第二电阻相同的阻值；
    第一双路运算放大器，用于产生2.5V的基准电压，其正端与第二电阻的另一端连接，负端与第一电容的一端连接，输出端与红外发射二极管的负端连接，负端还与红外发射二极管的负端连接；
    第一电容，另一端接地；
    第四电阻，一端与红外发射二极管的负端连接；
    第二双路运算放大器，正端与第四电阻的另一端连接，负端与红外接收二极管的正端连接，输出端作为脉搏电压；
    第五电阻，并联在第二双路运算放大器负端和第二双路运算放大器输出端之间；
    第二电容，并联在第二双路运算放大器负端和第二双路运算放大器输出端之间；
    红外发射二极管，设置在被测人员耳部毛细血管位置，用于发射红外光，红外发射二极管的负端与红外接收二极管的正端连接；
    红外接收二极管，设置在被测人员耳部毛细血管位置，位于所述红外发射二极管的相对位置，用于接收透射被测人员耳部毛细血管后的红外光；
    直接数字频率合成器，用于产生频率和相位能够调整的正弦波信号以作为射频频率源用作混频使用；
    脉冲序列发生器，用于产生脉冲序列；
    混频器，与所述直接数字频率合成器和所述脉冲序列发生器分别连接，采用脉冲序列对正弦波信号进行混频调制；
    功率放大器，与所述混频器连接，用于将混频调制后的信号进行放大；
    开关电源，用作探头与功率放大器之间的接口电路，将放大后的信号加载到探头的射频收发线圈中；
    钕铁硼永磁型磁体结构，在容纳被测人员手指的空间内产生一个场强均匀的静态磁场；
    探头，放置在被测人员手指位置，缠绕射频收发线圈以将加载的信号送入所述钕铁硼永磁型磁体结构内，产生核磁共振现象，还用于将经过被测人员手指内氢质子共振后获得的衰减信号送出；
    飞思卡尔IMX6处理器，与所述探头连接，接收所述衰减信号，分析所述衰减信号的谱线，并计算其中葡萄糖所占比例，从而获取被测人员的血糖浓度，所述飞思卡尔IMX6处理器还与所述第二双路运算放大器的输出端连接以获得所述脉搏电压，并当所述脉搏电压在 预设脉搏范围之外时，发出脉搏异常识别信号，当所述血糖浓度在预设血糖上限浓度时，发出血糖浓度过高识别信号，当所述血糖浓度在预设血糖下限浓度时，发出血糖浓度过低识别信号；
    胰岛素存储设备，用于预先存储预设容量的胰岛素；
    液位检测设备，位于所述胰岛素存储设备内，用于实时检测胰岛素存储设备内的胰岛素液位，并在胰岛素液位等于或低于预设基准液位时，发出胰岛素不足报警信号，所述液位检测设备还与所述飞思卡尔IMX6处理器连接以将所述胰岛素不足报警信号发送给所述飞思卡尔IMX6处理器；
    胰岛素驱动设备，与所述飞思卡尔IMX6处理器连接，当接收到所述血糖浓度过高识别信号时，根据所述飞思卡尔IMX6处理器转发的血糖浓度和所述预设血糖上限浓度的差值确定胰岛素泵驱动信号，所述胰岛素泵驱动信号决定了胰岛素泵的供应胰岛素的量值和速度；
    胰岛素泵，与所述胰岛素存储设备和胰岛素注射设备分别相接，与所述胰岛素驱动设备连接，用于在所述胰岛素驱动设备的控制下，将所述胰岛素存储设备内的胰岛素通过胰岛素注射设备注射到被测人员体内；
    胰岛素注射设备，可拆卸式埋设在被测人员体内，用于向被测人员注射胰岛素；
    串口通信电路，位于飞思卡尔IMX6处理器与蓝牙匹配通信设备之间，用于将所述血糖浓度和所述胰岛素不足报警信号发送到蓝牙匹配通信设备；
    蓝牙匹配通信设备，用于将所述血糖浓度和所述胰岛素不足报警信号无线发送到连接上的目标蓝牙设备；所述蓝牙匹配通信设备包括第一搜索子设备、第二搜索子设备和匹配连接子设备；其中，第一搜索子设备，根据蓝牙散射网中MAC地址浓度确定蓝牙MAC地址浓度最高的蓝牙微微网作为目标微微网，一个蓝牙散射网由多个蓝牙微微网组成；第二搜索子设备，与所述第一搜索子设备连接，在所述目标微微网中，寻找按信号强度排名在前的、数量不大于7的一个或多个蓝牙匹配通信设备作为一个或多个目标蓝牙设备；设备连接子设备，与所述第二搜索子设备连接，启动与所述一个或多个目标蓝牙设备的蓝牙通信连接；
    其中，当红外发射二极管和红外接收二极管之间无脉搏时，脉搏电压为2.5V，当红外发射二极管和红外接收二极管之间存在跳动的脉搏时，血脉使耳部透光性变差，脉搏电压大于2.5V；
    其中，第一双路运算放大器和第二双路运算放大器都为TI公司的双路运算放大器；
    其中，所述探头缠绕的射频收发线圈为鸟笼线圈、螺旋管线圈、鞍状线圈、相控阵列线圈和环状线圈中的一种；
    其中，直接数字频率合成器所采用的频率合成选用直接数字合成、模拟锁相环和数字锁相环中的一种；
    其中，当所述目标微微网中有信号的蓝牙匹配通信设备的数量为大于等于7时，所述一个或多个目标蓝牙设备的数量为7个，当所述目标微微网中有信号的蓝牙匹配通信设备的数量为小于7时，所述一个或多个目标蓝牙设备的数量为所述目标微微网中有信号的蓝牙匹配通信设备的数量。
  3. 如权利要求2所述的自动化血糖仪，其特征在于：
    所述串口通信电路为RS232串行通信接口。
  4. 如权利要求2所述的自动化血糖仪，其特征在于：
    所述飞思卡尔IMX6处理器在发出脉搏异常识别信号、血糖过高识别信号或血糖过低识别信号时，同时发出异常状态信号，否则，所述飞思卡尔IMX6处理器同时发出正常状态信号。
  5. 如权利要求4所述的自动化血糖仪，其特征在于，所述医学治疗仪还包括：
    无线通信电路，与所述飞思卡尔IMX6处理器连接，用于发送异常状态信号或正常状态信号。
  6. 如权利要求5所述的自动化血糖仪，其特征在于：
    所述无线通信电路为3G移动通信接口或4G移动通信接口。
  7. 如权利要求2所述的自动化血糖仪，其特征在于，所述医学治疗仪还包括：
    FLASH存储芯片，与所述飞思卡尔IMX6处理器连接，用于预先存储预设脉搏范围、预设血糖上限浓度和预设血糖下限浓度。
PCT/CN2016/096037 2015-11-05 2016-08-19 自动化血糖仪 WO2017076103A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680035610.2A CN107683108A (zh) 2015-11-05 2016-08-19 自动化血糖仪

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510747142.9A CN105232056B (zh) 2015-11-05 2015-11-05 医学治疗仪
CN201510747142.9 2015-11-05

Publications (1)

Publication Number Publication Date
WO2017076103A1 true WO2017076103A1 (zh) 2017-05-11

Family

ID=55030087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/096037 WO2017076103A1 (zh) 2015-11-05 2016-08-19 自动化血糖仪

Country Status (2)

Country Link
CN (3) CN105455823A (zh)
WO (1) WO2017076103A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112748684A (zh) * 2020-12-21 2021-05-04 许敬梅 基于rfid的智能胰岛素泵的监测控制系统及其装置

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105455823A (zh) * 2015-11-05 2016-04-06 张宏业 自动化血糖仪
CN105607530B (zh) * 2015-11-05 2016-12-14 华北理工大学 一种自动化血糖仪

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4875486A (en) * 1986-09-04 1989-10-24 Advanced Techtronics, Inc. Instrument and method for non-invasive in vivo testing for body fluid constituents
CN1414839A (zh) * 1999-12-28 2003-04-30 平迪产品公司 血糖非侵入性分析的方法和设备
CN101107025A (zh) * 2005-01-17 2008-01-16 诺和诺德公司 附有生理特征综合监测的流体输送装置
CN101125086A (zh) * 2006-08-18 2008-02-20 刘胜 闭环自动控制胰岛素注射系统
CN203564221U (zh) * 2013-10-17 2014-04-30 成都芮腾科技有限公司 脉搏信号拾取器
CN105232056A (zh) * 2015-11-05 2016-01-13 张宏业 自动化血糖仪
CN105607530A (zh) * 2015-11-05 2016-05-25 张宏业 一种基于自动化血糖仪的血糖检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008037316A2 (en) * 2006-09-28 2008-04-03 Werner Regittnig Device and method for determining a value of a physiological parameter of a body fluid
WO2008140554A2 (en) * 2006-10-24 2008-11-20 Medapps, Inc. Systems and methods for adapter-based communication with a medical device
CN102016855A (zh) * 2008-04-04 2011-04-13 海吉雅有限公司 用于优化患者的胰岛素剂量方案的装置
US8547239B2 (en) * 2009-08-18 2013-10-01 Cequr Sa Methods for detecting failure states in a medicine delivery device
BR112013033254A2 (pt) * 2011-06-23 2017-03-01 Univ Virginia Patent Foundation sistema para gerenciar o controle glicêmico de paciente e meio de armazenamento não transitório legível por computador
CN202939150U (zh) * 2012-11-29 2013-05-15 南京鱼跃软件技术有限公司 一种血糖仪
CN103263270A (zh) * 2013-05-02 2013-08-28 卢世明 血糖仪
CN204581297U (zh) * 2015-04-23 2015-08-26 何雷 一种基于脉搏波的胰岛素抵抗检测仪

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4875486A (en) * 1986-09-04 1989-10-24 Advanced Techtronics, Inc. Instrument and method for non-invasive in vivo testing for body fluid constituents
CN1414839A (zh) * 1999-12-28 2003-04-30 平迪产品公司 血糖非侵入性分析的方法和设备
CN101107025A (zh) * 2005-01-17 2008-01-16 诺和诺德公司 附有生理特征综合监测的流体输送装置
CN101125086A (zh) * 2006-08-18 2008-02-20 刘胜 闭环自动控制胰岛素注射系统
CN203564221U (zh) * 2013-10-17 2014-04-30 成都芮腾科技有限公司 脉搏信号拾取器
CN105232056A (zh) * 2015-11-05 2016-01-13 张宏业 自动化血糖仪
CN105455823A (zh) * 2015-11-05 2016-04-06 张宏业 自动化血糖仪
CN105607530A (zh) * 2015-11-05 2016-05-25 张宏业 一种基于自动化血糖仪的血糖检测方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN, KANG;: "Study on non-invasive blood glucose detection by magnetic resonance", MASTER'S DISSERTATION OF UNIVERSITY OF ELECTRONIC SCIENCE AND TECHNOLOGY OF CHINA, 15 April 2011 (2011-04-15), pages 15 *
WANG, XIANJING;: "Study on the new intelligent closed-loop insulin pump system", MASTER'S DISSERTATION OF QINGDAO TECHNOLOGICAL UNIVERSITY, 15 December 2013 (2013-12-15) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112748684A (zh) * 2020-12-21 2021-05-04 许敬梅 基于rfid的智能胰岛素泵的监测控制系统及其装置

Also Published As

Publication number Publication date
CN105455823A (zh) 2016-04-06
CN105232056B (zh) 2016-11-09
CN105232056A (zh) 2016-01-13
CN107683108A (zh) 2018-02-09

Similar Documents

Publication Publication Date Title
US10290208B2 (en) Methods for enabling a disabled capability of a medical device
WO2017076104A1 (zh) 无创式血糖仪
US20190254559A1 (en) Implantable Sensor and Method for Such Sensor
AU2014357567B2 (en) Bolus dosing feedback for the management of diabetes
WO2017076103A1 (zh) 自动化血糖仪
US10357180B2 (en) Health monitoring system
CN105193425A (zh) 一种无创式血糖仪的使用方法
US20140275843A1 (en) Continuous optode fluorescent measurement system
KR101169705B1 (ko) 실시간 혈당 측정에 의한 인슐린 투여 장치 및 이를 이용한 혈당 관리 시스템
CN105607530B (zh) 一种自动化血糖仪
CN105286884A (zh) 有创式血糖治疗仪
US9037209B2 (en) Bio-diagnostic testing system and methods
CN114746016A (zh) 用于减少计算的和测量的分析物水平之间差异的方法和系统
CN105496374B (zh) 增强计算机辅助医疗系统
US20230000401A1 (en) Methods and systems for reducing difference between calculated and measured analyte levels
Rosenbloom et al. Glucose microdialysis with continuous on-board probe performance monitoring
CN104090076A (zh) 一种远传网络血糖监测仪
Hedlund et al. Clinical experience with the Diametrics IRMA (Immediate Response Mobile Analysis) blood analysis system
CN114259228A (zh) 便携式肝储备功能检测装置及其检测方法
CN105288774A (zh) 有创式血糖治疗仪的使用方法
Schulz et al. Zigbee Network for Biomedical Signal Monitoring: Preliminary Results

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16861372

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16861372

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 16.07.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 16861372

Country of ref document: EP

Kind code of ref document: A1